Athersys, Inc. (ATHX)
| Market Cap | 360.80M |
| Revenue (ttm) | 457,000 |
| Net Income (ttm) | -66.48M |
| Shares Out | 197.34M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $1.83 |
| Previous Close | $1.85 |
| Change ($) | -0.02 |
| Change (%) | -1.08% |
| Day's Open | 1.89 |
| Day's Range | 1.79 - 1.94 |
| Day's Volume | 2,405,381 |
| 52-Week Range | 1.13 - 4.38 |
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host the year-end 2020 financial results call on March 25th.
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys and Healios commit to work in good faith to finalize negotiations important to successful commercialization in Japan.
CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Gil Van Bokkelen to Step Down as Chairman and CEO of Athersys
Athersys: Risky Financial Position, But Promising Upside By FYE 2023
CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host a virtual investor day event on February 16th to cover development progress and commercial manufacturing plans.
Athersys (ATHX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
The biotech announced the enrollment of the first patient in a key clinical study.
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--UTHealth and Athersys announce patient enrollment in an innovative clinical study of MultiStem® cell therapy for the treatment of traumatic inju...
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces three appointments to its board of directors, deepening board expertise to prepare for future growth and commercialization.
Athersys has taken its time in developing an interesting pipeline which has potential to offer outsized rewards. Athersys' US timeline for its ischemic stroke indication keeps challenging inve...
Athersys, Inc.'s (ATHX) CEO Gil Van Bokkelen on Q3 2020 Results - Earnings Call Transcript
Athersys, Inc. (ATHX) CEO Gil Van Bokkelen On Q3 2020 Results - Quick Version Earnings Call Transcript
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces Q3 earnings and initiation of MultiStem® Phase 2 clinical trial in patients with trauma related inflammation and complications
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results on Monday, November 9, 2020.
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--MultiStem is the only cell therapy program for acute respiratory distress syndrome (ARDS) that has both Fast Track and RMAT designation from the FDA.
Athersys, Inc. (ATHX) CEO Gil Van Bokkelen on Q2 2020 Results - Earnings Call Transcript
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial comp...
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2020 financial results on Monday, August 10, 2020.
The stem cell stock jumped after a major Wall Street firm initiated coverage, but there's a catch.
The stem cell stock recovered from a lousy April as the company fed investors updates for its COVID-19 programs.
Below is a list of six companies with promising Covid-19 treatments in various stages of development, and the reasons why I have invested in them.
Athersys Inc.s' (ATHX) CEO Gil Van Bokkelen on Q1 2020 Results - Earnings Call Transcript
The stem cell stock has delivered a 100% gain since the beginning of the year. Can it hold?
Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.
The stem cell developer decided to wisely take advantage of a soaring share price to raise funds.
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.
As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.
Shares of Athersys Inc. ATHX, -2.02% shot up 26.5% in premarket trading Monday, after the company said it has received Food and Drug Administration authorization to start a phase 2/3 trial to ...
Athersys Inc.: MultiStem Cell Therapy Is The Most Advanced And Tested Treatment For ARDS, And Thus COVID-19
Athersys - Now In Play For COVID-19 - FDA Fast Tracked Therapy For ARDS
Athersys' (ATHX) CEO Gil Van Bokkelen on Q4 2019 Results - Earnings Call Transcript
Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercialization of MultiStem® Highly experienced pharmaceutic...
One-year results support positive 28-day findings and suggest further benefits for ARDS patients One-year results support positive 28-day findings and suggest further benefits for ARDS patients
Designation will expedite review for HLCM051 (MultiStem® Cell Therapy) for ARDS program in Japan Designation will expedite review for HLCM051 (MultiStem® Cell Therapy) for ARDS program in Japan
Athersys, Inc. (ATHX) CEO Gil Van Bokkelen on Q3 2019 Results - Earnings Call Transcript
Conference being held October 2nd- 4th, 2019 in Carlsbad; live video webcast available Conference being held October 2nd- 4th, 2019 in Carlsbad; live video webcast available
We review significant developments in the last three months in our the stem cell triple play and how they create value moving forward.
Athersys, Inc. (ATHX) on Q2 2019 Results - Earnings Call Transcript
Understanding the basics of the stem cell sector.
The FDA has given the company's lead drug platform a potential leg up in development.
ATHX is developing a stem cell therapy that enlarges the window of treatment for ischemic strokes.
About ATHX
Athersys, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Pha... [Read more...]
| Industry Biotechnology | Founded 1995 |
| CEO Gil Van Bokkelen | Employees 83 |
| Stock Exchange NASDAQ | Ticker Symbol ATHX |
Financial Performance
In 2019, Athersys's revenue was $5.63 million, a decrease of -76.81% compared to the previous year's $24.29 million. Losses were -$44.58 million, 83.6% more than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for Athersys stock is "Strong Buy." The 12-month stock price forecast is 6.80, which is an increase of 271.58% from the latest price.